What is new on the treatment of #rheumatoid #arthritis? Check out the latest trial on #Ivarmacitinib (JAK1 oral inhibitor): ▶️ better ACR response at week 24 ▶️ sustained response through 52 weeks ▶️ manageable safety profile 🔗

Interested in #patient #education during transitional care? The latest @eular_org recommendations just released: 🚨 personalization of care, shared decision-making and interactive education ▶️ importance of physical activity & pain self-management 🔗

How can the link between smoking, lungs and joints be explained in #arthritis? According to a recent report, T cell dynamics could be response: ▶️ joint enrichment of CD4+ and CD8+ in smokers ▶️ TCR clonality ▶️ specific effector cell signature 🔗

What is new on #microbiome research in #arthritis? A recent study has found out in anti-CCP+ individuals progressors to RA ▶️ changes in Prevotellaceae abundance ▶️ microbiome instability before RA onset ▶️ concomitant changes in aminoacid metabolism 🔗

BMJ Group is seeking an ambitious and dynamic Editor in Chief for its new journal, BMJ Immunology, launching in 2025. Learn more and apply here before 15 December 2024: #researchers #clinicians

What does phenotype studies tell us in #psoriatic arthritis? Check out our latest report: ▶️ three stable clusters identified in PsA ▶️ associations with PsO and PsA severity ▶️ differences in response to immunosuppresive treatment, but not to TNFi 🔗

Check out the first international consensus of recommendations for managing chronic non-bacterial #osteitis in adults: ▶️ definition and differential diagnosis ▶️ imaging ▶️ therapeutics ▶️ outcome measures and follow-ups ▶️ adverse events 🔗

S1P1 receptor modulator cenerimod in SLE 🔴 Phase 2b 🔴 Sphingosine-1-phosphate: involved in lymphocyte egress from peripheral lymphoid organs ➡️ circulation 🔴 Cenerimod ⬇️ circulating AB-secreting cells & IFN-associated biomarkers 👉 4 mg in Ph3 🔗

PsA phenotype clusters & association with treatment response 🔴 Real-world longitudinal cohort study from PARC 🔴 627 pts 1️⃣ mild PsA & PsO only 47% 2️⃣ severe PsA & mild PsO 34% 3️⃣ severe PsA & severe PsO 18%: largest improvements in cDAPSA & PsAID 🔗

Real-life use of PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis & microscopic polyangiitis 🔴 Retrospective multicentre 🔴 redGC vs standGC in AAV 🔴 1️⃣ composite outcome= death, ESKD, relapse 👉 redGC associated with ⬆️ risk of primary outcome

Molecular basis for the disease-modifying effects of #belimumab in #lupus: ✅ neutrophil degranulation, type I interferon signalling and cytokine production👉 good response ❌cell cycle checkpoints, PI3K/Akt and TGF-beta signalling pathways👉bad response

BMJ Group is seeking an ambitious and dynamic Editor in Chief for its new journal, BMJ Immunology, launching in 2025. Learn more and apply here before 15 December 2024: #researchers #clinicians

🤔Is #glucocorticoid withdrawal possible in sustained inactive SLE patients? 👆 This study says yes, but better to keep hydroxychloroquine! Relapse rates 👉 GC and HCQ withdrawal 26.1% 👉 discontinued GC but maintained HCQ 11.2% 👉GC and HCQ continued 4.7%

RT @JOVREUM: #PodcastJOVREUM 🔸 La Dra @Belen_Miguel_ nos cuenta su trabajo sobre la importancia de la recuperación del estado funcional en…

RT @Dr_AndreRibeiro: 🚨 #ACR2024 was incredible! Grateful to the DUET team and everyone from @EMEUNET, @GrappaO, @PanlarJ and @Official_ASA…

EULAR points to consider for patient education in physical activity and self-management of pain during transitional care 🔹 clear aims, monitored and based on shared decision-making 🔹 interactiveprocess to manage the condition and optimise well-being

🚨 TREAT EARLIER - 4-year f/u: MTX could prevent RA in high-risk ACPA-negative patients? 📊 Patients with extensive MRI inflammation benefit most (HR 0.27). ⚠️ Correctly identifying high-risk populations is critical for effective disease interception. @Dr_AndreRibeiro #ACR24

#ACR24: The year of cell therapy in autoimmune diseases and redefining Tx paradigms! 🧬 Breakfree-1 CD19 CAR-T therapy shows sustained clinical remission in refractory #SLE and a safer profile. 🔬 Next-gen technology on the way. Stay tuned for more! @Dr_AndreRibeiro

💡 New hope for severe/refractory #SLE: A-319 (CD3 x CD19 TCE) shows rapid and safe immune reset! ✅ Rapid B-cell depletion, autoantibody reduction, & organ improvement by W2 ✅ No CRS or ICANS observed 📊 Could this be a game-changer in SLE therapy? @Dr_AndreRibeiro #ACR24

🚨 #ACR24: A urinary biomarker panel to predict histologically active LN⁉️ 💡 Highlights: ✅ AUC = 0.90 in cross-validation for 12 urine proteins ✅ Predictive value across proliferative & membranous classes Game-changer for non-invasive LN monitoring? @Dr_AndreRibeiro